- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05735587
Blueberries, Inflammation, Motivation, and Physical Activity
Dietary Intervention Targeting Inflammation, Motivation, and Engagement in Physical Activity in Sedentary, Older Adults With Depressive Symptoms
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The investigators will conduct a 14 week, single-site, randomized, double-blind, parallel pilot study in 40 sedentary, older adults with depressive symptoms. Participants will first enter a 2-week washout period where they will avoid consumption of foods high in fiber and anthocyanins (e.g., blueberries) and will also be wearing an activity monitor. Participants will then be randomized to consume either 48 g of freeze-dried blueberry powder (~600 mg of anthocyanins and ~8 g of fiber) or 48 g of a nutritionally matched placebo powder (devoid of anthocyanins and fiber) each day for a total of 12 weeks.
At baseline, participants will be undergo assessments for mood/well-being, relevant symptoms, motivation to engage in physical activity, and provide a blood sample for the evaluation of inflammatory biomarkers. For the entire duration of the study, participants will continue to wear the activity monitor. After 4, 6, 8 and 12 weeks of consuming the powder there will be study visits that assess mood/well-being, relevant symptoms, motivation to engage in physical activity and compliance with the intervention. Additionally, a blood sample for the evaluation of inflammatory makers will be taken after 6 and 12 weeks of the intervention.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Roslindale, Massachusetts, United States, 02131
- Hebrew Rehabilitation Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Men and women aged ≥65 years
- Self-reporting ≥ 8 hours of sitting per/day (e.g., sedentary behavior)
- Depressive symptoms (defined as ≥4 and <16 points on the center for epidemiological studies depression-scale)
Exclusion Criteria:
- Unwilling to follow the study protocol
- A median daily step count >7,500 steps per day (as measured by the ActiGraph), or per discretion of the PI
- Cognitive impairment (defined as Montreal Cognitive Assessment, MoCA <22 points)
- Self-reporting a history of inflammatory bowel disease/syndrome, major depression, bipolar, schizophrenia, or other psychotic disorders, or per discretion of the PI
- Self-reporting type 1 or type 2 diabetes
- Allergic to intervention or control products
- Recent use (within the last 3 months) of antibiotics, or per discretion of the PI
- Recent use (within the last 3 months) of pro-biotics, or per discretion of the PI
- Current substance use disorder (Drug Abuse Screening Test, DAST-10>2 points)
- Current alcohol use disorder (Alcohol Use Disorders Identification Test - Consumption, AUDIT-C≥4 points)
- Unstable anti-depressant use (e.g., change in medication within last 3-6 months), or per discretion of the PI
- Current homicidal or suicidal ideation (assessed via the P4 Suicidality Screener)
- Current psychosis (via the Psychosis and Hallucinations Questionnaire, PHQ>12 points)
- Manic symptoms (assessed by the Mood Disorder Questionnaire, MDQ >5 points)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Freeze-dried Blueberry Powder
Randomized participants will be asked to consume 48 grams of freeze-dried blueberry powder each day for 12 weeks.
|
Participants will be asked to consume 48 grams of freeze-dried blueberry powder (~ equivalent to 2 cups of fresh blueberries) daily for 12 weeks.
Participants will be asked to save any powder packet wrappers as a means to measure compliance.
They will also be instructed to avoid consumption of foods/beverages that are high in anthocyanins and/or fiber.
|
Placebo Comparator: Placebo Powder
Randomized participants will be asked to consume 48 grams of a nutritionally matched placebo powder devoid of fiber and anthocyanins each day for 12 weeks.
|
Participants will be asked to consume 48 grams of a nutritionally matched placebo powder (that does not contain fiber or anthocyanins) daily for 12 weeks.
Participants will be asked to save any powder packet wrappers as a means to measure compliance.
They will also be instructed to avoid consumption of foods/beverages that are high in anthocyanins and/or fiber.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Engagement in Physical Activity
Time Frame: Up to 12 weeks
|
Defined as median daily-step count over intervention
|
Up to 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Study Recruitment Feasibility
Time Frame: Through study completion, approximately 6 months
|
Participant retention (e.g., the number of participants that complete the intervention out of all participants randomized to an intervention arm)
|
Through study completion, approximately 6 months
|
Motivation
Time Frame: Up to 12 weeks
|
Motivation to engage in physical activity will be assessed via self-report questionnaire, Motives for Physical Activities Measure-Revised (range 0-30 points, with higher scores indicating higher levels of motivation).
|
Up to 12 weeks
|
Inflammatory Marker - C-Reactive protein
Time Frame: C-reactive protein (mg/dL) will be measured in blood collected from participants.
|
Up to 12 weeks
|
C-reactive protein (mg/dL) will be measured in blood collected from participants.
|
Inflammatory Marker - Interleukin-6
Time Frame: Interleukin-6 (pg/mL) will be measured in blood collected from participants.
|
Up to 12 weeks
|
Interleukin-6 (pg/mL) will be measured in blood collected from participants.
|
Inflammatory Marker - Brain derived neurotrophic factor
Time Frame: Brain derived neurotrophic (pg/mL) factor will be measured in blood collected from participants.
|
Up to 12 weeks
|
Brain derived neurotrophic (pg/mL) factor will be measured in blood collected from participants.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Courtney Millar, PhD, Hebrew SeniorLife, Marcus Institute of Aging, Harvard Medical Schools
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00064749
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depressive Symptoms
-
Finnish Institute for Health and WelfareUniversity of Helsinki; Tampere University; University of Eastern Finland; Strategic...RecruitingMajor Depressive Disorder | Depressive Symptoms Mild to Moderate in SeverityFinland
-
Julia EderNot yet recruitingDepressive Disorder | Depression | Depressive Symptoms | Major Depressive Disorder | Depressive EpisodeGermany
-
Medical Research CouncilKU LeuvenCompletedDepressive Symptoms | Major Depressive DisorderAustralia
-
Massachusetts General HospitalCompletedMajor Depressive DisorderUnited States, China
-
Dr. Nazanin AlaviCompletedDepression | Depressive Symptoms | Major Depressive DisorderCanada
-
Linkoeping UniversityCompletedMajor Depressive DisorderSweden
-
The University of Texas Health Science Center at...TerminatedDepression | Major Depressive DisorderUnited States
-
Santa Casa Medical SchoolFaculdade de Ciências Médicas da Santa Casa de São PauloUnknownDepressive SymptomsBrazil
-
State University of New York at BuffaloCompletedDepressive Symptoms | Major Depressive Disorder, Recurrent, in RemissionUnited States
-
University of TorontoKaiser Permanente; University of Colorado, BoulderCompletedDepressive Symptoms | Major Depressive Disorder, Recurrent, in RemissionUnited States
Clinical Trials on Freeze-dried Blueberry Powder
-
Hebrew SeniorLifeRecruitingAging | Depressive SymptomsUnited States
-
Florida State UniversityU.S. Highbush Blueberry CouncilCompleted
-
University of ReadingAlpro FoundationCompletedDose-dependent Effects of Blueberry Polyphenols on Endothelial Function in Healthy Individuals (BB2)Endothelial FunctionUnited Kingdom
-
Louisiana State University, Baton RougeU.S. Highbush Blueberry Council; Louisiana Health Care Practitioners, LLC; Collective... and other collaboratorsCompletedDepression | Inflammation | Depression, AnxietyUnited States
-
Clinical Nutrition Research Center, Illinois Institute...RecruitingInflammation | Insulin Resistance | Insulin Sensitivity | Pre-diabetesUnited States
-
University of East AngliaTerminated
-
University of Nevada, Las VegasUniversity of OklahomaRecruiting
-
USDA Human Nutrition Research Center on AgingTufts University; U.S. Highbush Blueberry CouncilCompletedAging | Age-Related Memory DisordersUnited States
-
Cornell UniversityCompletedSkeletal Muscle DisorderUnited States